 (Arch Dis Child 1996;75:159-161) 
OThal).
Interventions-Children over the age of 2 years received a single dose ofHib-tetanus toxoid conjugate vaccine (PRP-T). Main outcome measures -Antibody response to Hib polysaccharide (PRP) approximately one month after vaccination. Results -77 children over the age of 2 years were studied, 55 with HbSS, 16 with HbSC, and six with HbS-,Thal. Before vaccination, 44% had anti-PRP IgG titres less than the level associated with long term protection (1.0 igIml). After Children with sickle cell disease are at increased risk of infection with bacteria that contain a polysaccharide capsule. The most clearly demonstrated risk is in children with homozygous sickle cell disease (HbSS), who have been estimated to have a 500-1800-fold increased risk of pneumococcal meningitis and a case fatality rate for pneumococcal septicaemia of 44%, compared to 2-17% in otherwise healthy infants.' While the major pathogen in this group is Streptococcus pneumoniae, penicillin prophylaxis has proved successful in reducing the incidence of invasive S pneumoniae infection.2 A second important pathogen is Haemophilus influenzae type b (Hib) which accounts for a disproportionately large amount of infection in children of all ages with sickle cell disease compared to their healthy counterparts.3 4This risk has been estimated as 1/81 person years for children < 5 years of age with sickle cell disease, which is two to three times higher than the risk in normal children under 5 years of age.5 Within sickle cell disease the risk for invasive bacterial infection varies according to the form of the disease, those with HbSS. being at higher risk than those with sickle haemoglobin C disease (HbSC).i While splenic function is thought to be important in protecting individuals from invasive bacterial infection, the susceptibility of children with sickle cell disease to such infections cannot be attributed solely to splenic dysfunction and remains poorly understood. Before the introduction of conjugated Hib vaccines, pure Hib capsular polysaccharide vaccines were evaluated in children with sickle cell disease. They were shown to be non-immunogenic in children under the age of 18 months and poorly immunogenic in those from 18 months to 5 years.9 Hib conjugate vaccines, in contrast, have been shown to be highly immunogenic in healthy infants as young as 2 months of age'0 and their introduction into the routine infant immunisation programme has resulted in a dramatic decline in the incidence of invasive Hib disease in the UK."
As a result of the increased risk of bacterial infection in sickle cell disease, immunisation to protect children from both S pneumoniae and Hib infection is recommended in the USA by the American Academy of Pediatrics and the Centers for Disease Control, Atlanta.'2 However, the UK Department of Health makes no mention of sickle cell disease in its list of recommendations for Hib conjugate vaccine, but does recommend pneumococcal vaccination in this group." Routine Hib conjugate vaccination introduced in the U K in 1992 was targeted to children below 5 years of age; hence children born before 1988, including those with sickle cell disease, will have remained unimmunised.
The aim of this study was to establish baseline anti-Hib polysaccharide antibody titres in a group of children with sickle cell disease, to evaluate the immunogenicity of a single dose of Goldblatt Analysis of the prevaccination titre of anti-PRP IgG for the group as a whole showed that 12% (9/77) had an antibody titre < 0. 15 ,ug/ml, 32% (25/77) had an antibody titre > 0.15 and < 1.0 jg/ml, while 55% (43/77) had an antibody titre > 1.0 .g/ml. Following vaccination all study participants achieved a titre of anti-PRP antibody of > 1 jg/ml. Analysis of the correlation between age and the prevaccination anti-PRP titre showed there to be no positive correlation (r = 0.02) for the group as a whole. In addition there was no positive correlation between the age of the vaccinee and the magnitude of the postvaccination responses (r2= 0.01).
The geometric mean prevaccination antibody titre for the group as a whole was 1.0 jg/ml (95% confidence interval (CI) 0.75 to 1.34) and postvaccination, 45.2 jg/ml (95% CI 31.6 to 64.8). The geometric mean titre after vaccination was independent of ethnic background (p = 0.42). Interesting differences were noted for the subgroups of sickle cell disease (table 1). Before vaccination there was no difference between the geometric mean antibody titres for the three groups. However, after vaccination children with HbSC had a higher geometric mean antibody titre than the children with both HbS-PThal (p = 0.1) and HbSS (p = 0.026). All groups, however, achieved mean levels well above the accepted minimum protective level.
Discussion
Children with sickle cell disease are unduly susceptible to infection with encapsulated bacteria, and young children with sickle cell disease are particularly at risk.' 5 The susceptibility of this group stratifies according to the type of sickle cell disease. Children with HbSS are most at risk, while those with HbSC appear to be much less susceptible.' The basis for this difference is poorly understood, although it is clear that splenic function is lost earlier in HbSS than in HbSC.'6 Fatal infections with encapsulated organisms in children with HbSC have, however, been described4 17 and their risk of invasive infection is said to be higher than those of the general population. 4 5 Forty four per cent of the children in this study had a prevaccination titre of < 1.0 gg/ml, the level associated with long term protection in the healthy population. While 
